FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis
Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.
Tarsus launches Xdemvy at pharmacies nationwide
Lotilaner ophthalmic solution 0.25% (Xdemvy) was approved by the FDA in July, making it the first and only approved treatment for Demodex blepharitis.
Bausch + Lomb launches Infuse Multifocal SiHy daily disposable contact lenses in the US
Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.
IKA Keratoconus Symposium 2023: New data presented for epi-on cross-linking
John D. Gelles, OD, and Steven A. Greenstein, MD, share some insights into the new data on corneal cross-linking presented at IKA Keratoconus Symposium.
IKA Keratoconus Symposium 2023: Strategies for early diagnosis
At the IKA Keratoconus Symposium, Justin Schweitzer, OD, FAAO, presented on establishing the keratoconus diagnosis alongside Kourtney Houser, MD.
International Keratoconus Academy Symposium: What to expect
CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
New optics textbook aims to be a compendium resource for the topic
At AAO, Kamran Riaz, MD, discussed the new textbook, "Optics for the New Millennium," which is intended to be a compendium resource for ophthalmologists.
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Jeff Nau, PhD, MMS, President and CEO of Oyster Point Pharmaceuticals, provides an appraisal of the company's pipeline as well as updates on recent innovations to hit the market.
ViaLase seeks to disrupt glaucoma treatment paradigm with new femtosecond laser treatment
Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.
Contralateral eye study investigates iStent vs Hydrus stent for glaucoma
At AAO 2022, Mitch Shultz, MD, provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.
Trukera Medical rebranding allows team to expand into the broader corneal health market
Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.
Assessing the effectiveness of netarsudil and episcleral blood flow in treatment-naive glaucoma suspects, hypertension subject
Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."
Higher rates of repeat corneal crosslinking need found in younger patients
At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.
Choosing among DSAEK, DMEK and DSO for endothelial keratoplasty
Kathryn A. Colby, MD, PhD, sits down with Ophthalmology Times to discuss her 2022 AAO presentation: "Endothelial Keratoplasty Should I Choose? DSAEK, DMEK, DSO"
Post hoc analysis of varenicline solution OC-01 shows promise for dry eye patients undergoing anticholinergic therapy
At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."
Positive visual outcomes reported one year following monocular implantation of small aperture IOL
Mark H. Blecher, MD, dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."
Discussing how fluid dynamic affect visual acuity in wet macular degeneration
At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Novel glasses, designed for children with cranial dysotosis, help doctors provide functional eyewear for children in underserved communities, says Donny Suh, MD.
Reviewing the AAO cornea preferred practice patterns: Corneal edema, opacifications, ectasia and bacterial keratitis
David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.
Dispersive ophthalmic viscosurgical device found to be safe, effective in clinical trials
Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."
Visus Therapeutics CEO announces acquisition of ViewPoint Therapeutics to expand on cataract, presbyopia candidate
Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.
Faricimab: YOSEMITE, RHINE treat-and-extend data illustrate favorable personalized treatment dynamics for the treatment of DME
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
Poll results: Are you attending AAO in Chicago?
Results from our recent poll regarding AAO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Chicago, Illinois.
POLL: Are you attending AAO in Chicago?
We're polling ophthalmologists about attendance at the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois. The poll is now closed.
Wykoff: RGX-314 highlights DRSS improvements in patients diagnosed with DME, NPDR
Charles Wykoff, MD, took the stage at the American Society of Retina Specialists annual meeting in New York to present a talk titled “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” He discusses results of the trial, which showed improvements for patients diagnosed with diabetic macular edema and non-proliferative diabetic retinopathy, with notable improvements according to the Diabetic Retinopathy Severity Scale.
Use of aflibercept in the management of diabetic retinopathy
Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.
What the impact of 44-week aflibercept data may mean in a real-world setting
David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.
VIEW 1 and VIEW 2 studies: taking a deeper dive
Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.
2 Clarke Drive Cranbury, NJ 08512